<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388464</url>
  </required_header>
  <id_info>
    <org_study_id>SPIHF-101</org_study_id>
    <nct_id>NCT02388464</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure</brief_title>
  <official_title>A Phase 1 Clinical Pharmacology Study of the Effects of a Single 4 Hour Intravenous Infusion of Bendavia™ (MTP-131) in Subjects With Stable New York Heart Association Class II-III Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-center, randomized, double-blind, single ascending dose,
      placebo-controlled study, in subjects aged 45-80 years with stable mild to moderate heart
      failure due to left ventricular systolic dysfunction, to evaluate the safety, tolerability,
      and pharmacokinetics of escalating single intravenous infusion doses of Bendavia™ (MTP-131).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Assessed up to Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction assessed by 2-D echocardiography</measure>
    <time_frame>Assessed up to 24 hours post-infusion start</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTP-131</intervention_name>
    <description>MTP-131 (low dose) administered as single intravenous infusion over 4 hours</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTP-131</intervention_name>
    <description>MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours</description>
    <arm_group_label>Intermediate dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTP-131</intervention_name>
    <description>MTP-131 (high dose) administered as single intravenous infusion over 4 hours</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic ischemic or non-ischemic cardiomyopathy of at least 6 months duration from the
             time of the initial diagnosis.

          -  LVEF ≤35% by 2-D echocardiogram.

          -  Diagnosis of NYHA Class II or III HF for a minimum of 6 months prior to the Screening
             Visit.

          -  HF is considered to be stable and no hospitalization for HF has occurred within the
             previous 3 months prior to the Screening visit.

          -  Treatment with appropriate pharmacologic therapy for HF including, but not limited to,
             angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker
             (ARB), and an evidence-based beta blocker for the treatment of HF (i.e. carvedilol,
             bisoprolol, or extended-release metoprolol).

          -  Dose and dose regimen of pharmacologic treatments for HF must be stable for a minimum
             of 1 month prior to the Screening Visit.

          -  Females of child-bearing potential must have a negative serum pregnancy test at the
             Screening Visit and Day 1.

        Exclusion Criteria:

          -  LV end-diastolic dimension (LVEDD), by the same method as qualifying LVEF, is &gt;80 mm
             or LVEDD indexed to body surface area is &gt;0.45.

          -  Unstable angina pectoris within 1 month before initiation of screening procedures.
             Unstable angina is defined as the occurrence of chest pain more frequently than usual,
             pain at rest or upon minimal exertion, or protracted episodes of pain without any
             discernible trigger, and/or chest pain that persists despite use of vasodilatory
             therapy (e.g., nitroglycerin).

          -  Coronary or peripheral artery revascularization procedure within 2 months prior to the
             Screening Visit.

          -  An acute myocardial infarction within 3 months prior to the Screening Visit.

          -  Placement of an automated implantable cardioverter defibrillator (AICD) or any
             hardware associated with resynchronization therapy.

          -  Atrial fibrillation at the Screening or Baseline Visits.

          -  Uncontrolled hypertension defined as a systolic blood pressure (BP) &gt; 180 mm Hg or a
             diastolic BP &gt;110 mm Hg on at least 2 consecutive readings.

          -  Requirement for valve or other cardiac surgery

          -  Cardiac surgery or valvuloplasty within 2 months prior to the Screening Visit.

          -  General surgery within 1 month prior to the Screening Visit

          -  Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease,
             amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic
             left ventricular aneurysm.

          -  Cerebrovascular accident or transient ischemic attack within 3 months prior to the
             Screening Visit.

          -  Estimated glomerular filtration rate (eGFR) &lt;40 mL/min, using the Modification of Diet
             in Renal Disease (MDRD) Study equation

          -  Serologic evidence of hepatitis B or C infection.

          -  Known acquired immunodeficiency syndrome or HIV-positive status, or diagnosis of
             immunodeficiency.

               -  Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Carr, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Stealth BioTherapeutics Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sotir Marchev, MD,PhD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bulgaria</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sevlievo</city>
        <state>Gabrovo</state>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Bendavia™</keyword>
  <keyword>MTP-131</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

